NEW YORK (GenomeWeb) – The Geisinger Health System has struck a partnership with German personalized cancer services company Indivumed to collect and study patient samples and develop targeted treatments, the partners said today.

The agreement will enable Indivumed and Geisinger to collect samples from consenting patients who are already undergoing a surgical tumor resection. The partners will store portions of those tissue, blood, or urine samples at Geisinger via the MyCode repository, and in an Indivumed bank, where they will be analyzed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.

The US Supreme Court has declined to review a decision involving the use of "inadvertently shed" DNA in a police investigation and subsequent conviction.

A panel at the New York Times discusses anonymity and privacy of users of 23andMe's services when access to its database is offered for research.

National Institutes of Health Director Francis Collins appears before a House subcommittee to discuss his agency's budget request.